Anne Keating, BS, Pharm.D., is Frontier’s Senior Vice President, Head of Clinical Development Operations and Program Management.   Anne’s role at Frontier includes advancing our platform compounds into the clinic and ultimately obtaining regulatory approval. Anne leads our cross-functional teams to formulate streamline, robust development strategies considering potential risks, opportunities and mitigations including adapting to changes in the competitive landscape. Anne is also responsible for overseeing the execution of the development strategy through collaboration with external vendors and other key stakeholders.  

Prior to joining Frontier, Anne held multiple leadership positions across the clinical development organization at Astellas.  She was Vice President, Head of Global Development Team Leaders and was responsible for  delivering globally a portfolio of compounds spanning preclinical to post-approval.  Anne oversaw the entire Astellas portfolio which included multiple therapeutic areas (e.g., Oncology, Rare Disease, etc.) and modalities. Under Anne’s leadership, as Head of Clinical Science, her teams designed and implemented the clinical studies aimed at new or expanded approvals for micafungin, gilteritinib, enfortumab vedotin, fezolinitant, and zolbetuxumab. 

Prior to joining Astellas, Anne was an Associate Director, Clinical Operations at Abbott Laboratories. During her time at Abbott, Anne held roles in a variety of different functions including Clinical Operations, Project Management and Program Management which provided her a solid clinical development foundation. 

Anne holds a B.S in Biology from Loyola University of Chicago and an Pharm.D. from the University of Illinois at Chicago (UIC) College of Pharmacy Chicago. She is licensed in Illinois as a pharmacist.